CN101557831A - 体内抑制在灵长类亨廷顿基因表达的方法和序列 - Google Patents

体内抑制在灵长类亨廷顿基因表达的方法和序列 Download PDF

Info

Publication number
CN101557831A
CN101557831A CNA2007800372445A CN200780037244A CN101557831A CN 101557831 A CN101557831 A CN 101557831A CN A2007800372445 A CNA2007800372445 A CN A2007800372445A CN 200780037244 A CN200780037244 A CN 200780037244A CN 101557831 A CN101557831 A CN 101557831A
Authority
CN
China
Prior art keywords
nucleic acid
expression
sequence
seq
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800372445A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·D·凯特
威廉姆·F·卡恩米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Publication of CN101557831A publication Critical patent/CN101557831A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2007800372445A 2006-08-09 2007-08-08 体内抑制在灵长类亨廷顿基因表达的方法和序列 Pending CN101557831A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/501,634 2006-08-09
US11/501,634 US7902352B2 (en) 2005-05-06 2006-08-09 Isolated nucleic acid duplex for reducing huntington gene expression

Publications (1)

Publication Number Publication Date
CN101557831A true CN101557831A (zh) 2009-10-14

Family

ID=39082580

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800372445A Pending CN101557831A (zh) 2006-08-09 2007-08-08 体内抑制在灵长类亨廷顿基因表达的方法和序列

Country Status (5)

Country Link
US (1) US7902352B2 (https=)
EP (1) EP2056881A4 (https=)
JP (1) JP2010500025A (https=)
CN (1) CN101557831A (https=)
WO (1) WO2008021136A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
DK2821085T3 (da) * 2003-09-12 2020-08-03 Univ Massachusetts Rna-interferens til behandling af "gain-of-function"-forstyrrelser
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
WO2006121960A2 (en) 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
EP1937066A4 (en) 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
CA2670967C (en) 2006-11-29 2016-05-10 University Of Iowa Research Foundation Alternative export pathways for vector expressed rna interference
EP2152874A2 (en) 2007-04-26 2010-02-17 University of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
DK2164967T3 (en) 2007-05-31 2015-10-19 Univ Iowa Res Found Reduction of off-target rna interferenstoksicitet
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN102124109B (zh) * 2008-06-30 2013-10-16 Cho-A制药有限公司 猪α-S1-酪蛋白基因，其启动子及其用途
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
WO2012109667A1 (en) 2011-02-12 2012-08-16 University Of Iowa Research Foundation Therapeutic compounds
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
EP3146051B8 (en) 2014-05-20 2019-11-27 University of Iowa Research Foundation Huntington's disease therapeutic compounds
CR20170406A (es) 2015-02-10 2017-11-14 Genzyme Corp Arni variante
IL320434A (en) 2015-07-22 2025-06-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods
EP3452596A4 (en) 2016-05-04 2020-03-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
CN111356763B (zh) 2017-09-22 2024-03-12 建新公司 变体RNAi
EP4314296A2 (en) 2021-03-29 2024-02-07 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
GB2181691B (en) * 1985-10-21 1990-05-23 Porvair Ltd Gloves
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
CA2109955A1 (en) * 1991-05-24 1992-11-26 Toru Hayakawa Equipment for intracerebral administration of preparations
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
US5354326A (en) * 1993-01-27 1994-10-11 Medtronic, Inc. Screening cable connector for interface to implanted lead
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
US5849995A (en) * 1993-09-27 1998-12-15 The University Of British Columbia Mouse model for Huntington's Disease and related DNA sequences
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
CA2179014C (en) * 1993-12-17 2003-07-29 Spinal Cord Society Method for inducing dna synthesis in neurons
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US6294202B1 (en) * 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5534350A (en) * 1994-12-28 1996-07-09 Liou; Derlin Powerfree glove and its making method
US7069634B1 (en) 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
WO1996033761A1 (en) * 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
US5840059A (en) * 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5942455A (en) * 1995-11-14 1999-08-24 Drexel University Synthesis of 312 phases and composites thereof
JPH09268067A (ja) * 1996-03-29 1997-10-14 Asahi Glass Co Ltd 炭化ケイ素部材の製造方法
WO2000062828A1 (en) * 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US7189222B2 (en) * 1996-04-30 2007-03-13 Medtronic, Inc. Therapeutic method of treatment of alzheimer's disease
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
WO1998012311A2 (en) * 1996-09-11 1998-03-26 The General Hospital Corporation Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
US5882561A (en) * 1996-11-22 1999-03-16 Drexel University Process for making a dense ceramic workpiece
GB9701684D0 (en) * 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US5968059A (en) * 1997-03-06 1999-10-19 Scimed Life Systems, Inc. Transmyocardial revascularization catheter and method
GB9706463D0 (en) * 1997-03-27 1997-05-14 Medical Res Council A model of inflamation in the central nervous system for use in the study of disease
NZ333334A (en) * 1997-04-17 2001-06-29 Frank L Sorgi Delivery system for gene therapy to the brain
US5782892A (en) * 1997-04-25 1998-07-21 Medtronic, Inc. Medical lead adaptor for external medical device
US5931861A (en) * 1997-04-25 1999-08-03 Medtronic, Inc. Medical lead adaptor having rotatable locking clip mechanism
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6110459A (en) * 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
US20050282198A1 (en) 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6231969B1 (en) * 1997-08-11 2001-05-15 Drexel University Corrosion, oxidation and/or wear-resistant coatings
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6151525A (en) * 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
DE19938960A1 (de) 1998-03-10 2001-02-22 Bisping Hans Juergen Testkabelanordnung
US6436392B1 (en) * 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
WO1999061066A2 (en) * 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6319905B1 (en) * 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
WO2000065042A1 (en) * 1999-04-28 2000-11-02 The Board Of Trustees Of The Leland Stanford Junior University P element derived vector and methods for its use
GB9928248D0 (en) * 1999-12-01 2000-01-26 Gill Steven S An implantable guide tube for neurosurgery
US6310048B1 (en) * 1999-12-09 2001-10-30 St. Louis University Antisense modulation of amyloid beta protein expression
US6461989B1 (en) * 1999-12-22 2002-10-08 Drexel University Process for forming 312 phase materials and process for sintering the same
US20030092003A1 (en) * 1999-12-29 2003-05-15 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of Alzheimer's disease
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
JP4751556B2 (ja) * 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
US6468524B1 (en) * 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6945969B1 (en) * 2000-03-31 2005-09-20 Medtronic, Inc. Catheter for target specific drug delivery
US6551290B1 (en) * 2000-03-31 2003-04-22 Medtronic, Inc. Catheter for target specific drug delivery
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20020042388A1 (en) * 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
AU2001288317A1 (en) * 2000-08-30 2002-03-13 Agion Technologies, Llc Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US6659995B1 (en) 2000-11-17 2003-12-09 Syde A. Taheri Autologous myocyte micro granual retrieval and implantation (AMMGRI)
CA2327208A1 (en) * 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US7182944B2 (en) 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
EP1389194A2 (en) * 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US20050282188A1 (en) 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050277133A1 (en) 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
CA2450809A1 (en) * 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
WO2003013437A2 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
US6944497B2 (en) * 2001-10-31 2005-09-13 Medtronic, Inc. System and method of treating stuttering by neuromodulation
US8274559B2 (en) * 2001-11-09 2012-09-25 Karl Storz Imaging, Inc. Replaceable hardware component of a camera control unit for video systems
US20030120282A1 (en) * 2001-12-24 2003-06-26 Scouten Charles W. Stereotaxic manipulator with retrofitted linear scales and digital display device
US7294504B1 (en) * 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
US7270653B2 (en) * 2002-02-20 2007-09-18 Abbott Research Group Methods of treating abnormal biological conditions using metal oxides
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030224512A1 (en) 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
US20040023855A1 (en) * 2002-04-08 2004-02-05 John Constance M. Biologic modulations with nanoparticles
US20040018520A1 (en) * 2002-04-22 2004-01-29 James Thompson Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein
US7008403B1 (en) * 2002-07-19 2006-03-07 Cognitive Ventures Corporation Infusion pump and method for use
JP3968365B2 (ja) 2002-07-25 2007-08-29 日世株式会社 ロールコーン製造装置
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US20050048641A1 (en) * 2002-11-26 2005-03-03 Medtronic, Inc. System and method for delivering polynucleotides to the central nervous system
US7605249B2 (en) * 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
JP2004232811A (ja) 2003-01-31 2004-08-19 Hitachi Unisia Automotive Ltd 補機駆動用電磁クラッチ
US8946151B2 (en) * 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040186528A1 (en) 2003-03-20 2004-09-23 Medtronic, Inc. Subcutaneous implantable medical devices with anti-microbial agents for chronic release
US8512290B2 (en) * 2003-03-20 2013-08-20 Boston Scientific Scimed, Inc. Devices and methods for delivering therapeutic or diagnostic agents
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
EP1620133B1 (en) 2003-05-01 2015-12-09 Genzyme Corporation Gene therapy for neurometabolic disorders
US7917228B2 (en) 2003-05-13 2011-03-29 Medtronic, Inc. Medical lead adaptor assembly
US7589189B2 (en) 2003-05-14 2009-09-15 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
DK2821085T3 (da) 2003-09-12 2020-08-03 Univ Massachusetts Rna-interferens til behandling af "gain-of-function"-forstyrrelser
WO2005065242A2 (en) * 2003-12-29 2005-07-21 Am Biosolutions Method of treating cancer using platelet releasate
US20050153353A1 (en) * 2004-01-09 2005-07-14 Bernd Meibohm Real-time polymerase chain reaction-based genotyping assay for beta2-adrenergic receptor single nucleotide polymorphism
US20050202075A1 (en) * 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
WO2005096781A2 (en) 2004-04-06 2005-10-20 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using rna interference
WO2005105995A2 (en) 2004-04-14 2005-11-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2005116204A1 (ja) 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
WO2006022639A1 (en) 2004-07-21 2006-03-02 Applera Corporation Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
WO2006047250A2 (en) * 2004-10-22 2006-05-04 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
NL1028134C2 (nl) * 2005-01-27 2006-07-31 Sara Lee De Nv Werkwijze voor het bereiden van een voor consumptie geschikte drank uit ten minste twee op te lossen en/of te extraheren ingredienten en een hoeveelheid vloeistof.
TW200635542A (en) * 2005-04-01 2006-10-16 Dharma Drum Mountain Method of establishing and using commemorative material
WO2006121960A2 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
US20080280843A1 (en) 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
GB0520235D0 (en) 2005-10-05 2005-11-16 Astrazeneca Ab Method
JP5111385B2 (ja) * 2005-10-28 2013-01-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド ハンチンチン遺伝子の発現を抑制するための組成物および方法
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
US20080039415A1 (en) 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CN200970210Y (zh) 2006-10-12 2007-11-07 王会才 拖把清洗脱水机

Also Published As

Publication number Publication date
EP2056881A2 (en) 2009-05-13
EP2056881A4 (en) 2010-10-20
JP2010500025A (ja) 2010-01-07
US7902352B2 (en) 2011-03-08
US20100325746A9 (en) 2010-12-23
WO2008021136A3 (en) 2008-07-03
WO2008021136B1 (en) 2008-08-07
US20070261126A1 (en) 2007-11-08
WO2008021136A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
CN101557831A (zh) 体内抑制在灵长类亨廷顿基因表达的方法和序列
US8258112B2 (en) Methods and sequences to suppress primate huntington gene Expression
JP5922721B2 (ja) 神経筋シナプスの維持および再生に関与するマイクロｒｎａの同定
RU2711147C2 (ru) Терапевтические соединения для лечения болезни хантингтона
EP1799826B1 (en) siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN
KR101965868B1 (ko) 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
JP2008500049A (ja) ｓｉＲＮＡの頭蓋内デリバリーによる神経変性疾患の治療
PT2029746E (pt) Composições e métodos para a inibição do sirna de angiogenese
JP2011513238A (ja) 平滑筋の増殖および分化を調節するマイクロｒｎａならびにこれらの使用
US20110117627A1 (en) Regulation of apoptosis by neural specific splice variants of ig20
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
CN101522202A (zh) 通过颅内递送sirna治疗亨廷顿氏舞蹈症的组合物、装置和方法
Enomoto et al. Efficient gene suppression in dorsal root ganglia and spinal cord using adeno-associated virus vectors encoding short-hairpin RNA
KR20100029079A (ko) Ｇｐｒ12의 저해로 인지 질환을 치료하는 방법
WO2009003211A1 (en) Treatment of rheumatoid arthritis
AU2025259971A1 (en) Compositions and methods for the treatment of anesthesia-induced neurotoxicity
JP2022064910A (ja) 副腎脊髄ニューロパチーの治療のためのａｂｃｄ１をコードする核酸配列の髄腔内送達
US20240026359A1 (en) Methods of Treating of Spinal Stenosis and Ligamentum Flavum Hypertrophy
Zhang Antisense Therapy in Mouse Models of Histone H3. 3k27m Diffuse Midline Glioma Inhibits Tumor Growth, Promotes Neural and Glial Differentiation
CN120584186A (zh) 用于在静脉血栓栓塞的治疗中使用的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091014